Phase I Trial of TAS-102 and Concurrent Radiation Therapy for Patients With Locally Recurrent, Unresectable or Metastatic, Rectal Cancer

Trial Profile

Phase I Trial of TAS-102 and Concurrent Radiation Therapy for Patients With Locally Recurrent, Unresectable or Metastatic, Rectal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Adenocarcinoma; Rectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Jun 2018 Status changed from suspended to recruiting.
    • 05 Jun 2018 Study design presented at the 54th Annual Meeting of the American Society of Clinical Oncology. This trial is currently accruing patients to the first cohort.
    • 08 May 2018 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top